Legal & General Group PLC Ultragenyx Pharmaceutical Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 101,912 shares of RARE stock, worth $4.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,912
Previous 101,912 -0.0%
Holding current value
$4.56 Million
Previous $5.66 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$40.21 - $59.36 $342,267 - $505,272
8,512 Added 9.11%
101,912 $5.66 Million
Q2 2024

Aug 14, 2024
BUY
$37.42 - $51.61 $356,650 - $491,894
9,531 Added 11.36%
93,400 $3.84 Million
Q1 2024

May 14, 2024
BUY
$43.02 - $53.69 $474,811 - $592,576
11,037 Added 15.15%
83,869 $3.92 Million
Q4 2023

Feb 15, 2024
BUY
$31.73 - $49.19 $123,715 - $191,791
3,899 Added 5.66%
72,832 $3.48 Million
Q3 2023

Nov 14, 2023
SELL
$34.92 - $46.66 $1.33 Million - $1.77 Million
-37,978 Reduced 35.52%
68,933 $2.46 Million
Q2 2023

Aug 14, 2023
SELL
$37.35 - $52.15 $277,249 - $387,109
-7,423 Reduced 6.49%
106,911 $4.93 Million
Q1 2023

May 15, 2023
BUY
$36.99 - $48.71 $932,628 - $1.23 Million
25,213 Added 28.29%
114,334 $4.58 Million
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $156,393 - $214,878
4,638 Added 5.49%
89,121 $4.13 Million
Q3 2022

Nov 14, 2022
BUY
$39.96 - $66.14 $292,267 - $483,747
7,314 Added 9.48%
84,483 $3.5 Million
Q2 2022

Aug 22, 2022
BUY
$45.8 - $85.4 $103,920 - $193,772
2,269 Added 3.03%
77,169 $4.6 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $350,559 - $475,678
5,636 Added 8.14%
74,900 $5.44 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $258,943 - $308,652
3,513 Added 5.34%
69,264 $5.83 Million
Q3 2021

Nov 15, 2021
BUY
$77.92 - $102.4 $1.26 Million - $1.65 Million
16,133 Added 32.51%
65,751 $5.93 Million
Q2 2021

Aug 12, 2021
BUY
$92.19 - $115.71 $2,673 - $3,355
29 Added 0.06%
49,618 $4.73 Million
Q1 2021

May 17, 2021
SELL
$106.9 - $167.73 $56,443 - $88,561
-528 Reduced 1.05%
49,589 $5.65 Million
Q4 2020

Feb 12, 2021
BUY
$84.4 - $177.39 $494,246 - $1.04 Million
5,856 Added 13.23%
50,117 $6.94 Million
Q3 2020

Nov 13, 2020
SELL
$72.98 - $90.0 $204,708 - $252,450
-2,805 Reduced 5.96%
44,261 $3.64 Million
Q2 2020

Aug 14, 2020
BUY
$46.91 - $78.22 $369,416 - $615,982
7,875 Added 20.09%
47,066 $3.68 Million
Q1 2020

May 14, 2020
SELL
$33.8 - $62.9 $86,426 - $160,835
-2,557 Reduced 6.12%
39,191 $1.74 Million
Q4 2019

Feb 13, 2020
BUY
$36.08 - $45.83 $241,447 - $306,694
6,692 Added 19.09%
41,748 $1.78 Million
Q3 2019

Nov 13, 2019
BUY
$42.5 - $63.11 $187,722 - $278,756
4,417 Added 14.42%
35,056 $1.5 Million
Q2 2019

Aug 14, 2019
BUY
$54.93 - $74.36 $46,305 - $62,685
843 Added 2.83%
30,639 $1.95 Million
Q1 2019

May 15, 2019
BUY
$39.87 - $69.36 $363,175 - $631,800
9,109 Added 44.03%
29,796 $2.07 Million
Q4 2018

Feb 15, 2019
BUY
$38.89 - $77.3 $128,648 - $255,708
3,308 Added 19.03%
20,687 $899,000
Q3 2018

Nov 20, 2018
BUY
$71.81 - $90.15 $100,749 - $126,480
1,403 Added 8.78%
17,379 $1.33 Million
Q2 2018

Aug 10, 2018
SELL
$48.54 - $85.31 $216,003 - $379,629
-4,450 Reduced 21.79%
15,976 $1.23 Million
Q1 2018

May 17, 2018
SELL
$44.33 - $58.52 $5.85 Million - $7.72 Million
-131,906 Reduced 86.59%
20,426 $1.04 Million
Q4 2017

Feb 13, 2018
BUY
$43.54 - $57.32 $6.63 Million - $8.73 Million
152,332
152,332 $7.07 Million

Others Institutions Holding RARE

# of Institutions
325
Shares Held
85.7M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email